Stockscreener 앱 받기
0.3376
8.76%
-0.0324
시간 외 거래:
.33
-0.0076
-2.25%
Tonix Pharmaceuticals Holding Corp 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 151.6% in December - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 8.7%Time to Sell? - MarketBeat
This Micro Cap Is Getting Bid Up Prior To Opening Bell - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.6%Should You Sell? - MarketBeat
Certain Options of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Certain Common Stock of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 4.4%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.2%What's Next? - MarketBeat
FDA sets review goal date for Tonix fibromyalgia drug By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 26.8%Should You Sell? - MarketBeat
Tonix Pharma Awaits FDA Decision on TNX-102 SL - TipRanks
FDA sets review goal date for Tonix fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces PDUFA Goal Date of August - GlobeNewswire
Tonix Pharmaceuticals' Groundbreaking Fibromyalgia Drug Gets FDA Fast Track & PDUFA Date - StockTitan
StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Tonix Pharmaceuticals ups offering to $250 million - Investing.com India
Tonix Pharmaceuticals ups offering to $250 million By Investing.com - Investing.com Canada
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 11.3%Here's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.7%Should You Sell? - MarketBeat
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application for Tnx-102 Sl for Fibromyalgia - Marketscreener.com
FDA accepts new fibromyalgia drug application from Tonix Pharma By Investing.com - Investing.com Australia
FDA Accepts NDA for Tonix’s Sleep-Improving Drug for Fibromyalgia - Sleep Review
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
TSX 60 Capped Index (TXCI) QuotePress Release - The Globe and Mail
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone - TipRanks
Nasdaq 100 Index (IUXX) QuotePress Release - The Globe and Mail
What's Going On With Tonix Pharmaceuticals Stock Today? - Benzinga
FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL - Invezz
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Tonix Pharmaceuticals Gets FDA Review of Fibromyalgia Drug - Marketscreener.com
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
FDA accepts new fibromyalgia drug application from Tonix Pharma - Investing.com
Tonix Pharmaceuticals Announces FDA Acceptance of the New - GlobeNewswire
Tonix's Breakthrough Fibromyalgia Drug Takes Major Step Forward with FDA NDA Acceptance - StockTitan
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - citybiz
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
Certain Options of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 11-DEC-2024. - Marketscreener.com
Certain Common Stock of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 11-DEC-2024. - Marketscreener.com
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers - BioSpace
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on January 25, 2023. - Marketscreener.com
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on September 6, 2024. - Marketscreener.com
Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires - GlobeNewswire
TNXP: NDA Filed for TNX-102 SL in Fibromyalgia… - Yahoo Finance
Tonix Pharmaceuticals Holding (STU:TPM0) Operating Income : €-74.27 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EBITDA per Share : €-24.48 (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) FCF Yield % : -195.15 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) EV-to-Revenue : 1.46 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) Capex-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) PS Ratio : 27.04 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Inventories, Inven - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Long-Term Debt : €4.66 Mil (As of Sep. 2024) - GuruFocus.com
2.14%
5.55%
자본화:
|
볼륨(24시간):